Trials / Unknown
UnknownNCT00337389
Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.
A Phase III Multi-Center Randomized Clinical Trial to Evaluate the Safety and Efficacy of CoFactor and 5-Fluorouracil (5-FU) Plus Bevacizumab Versus Leucovorin and 5-FU Plus Bevacizumab as Initial Treatment for Metastatic Colorectal Carcinoma
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,200 (estimated)
- Sponsor
- Mast Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To compare the progression-free survival time (PFS) in patients treated with 5-FU modulated with CoFactor (plus bevacizumab) to 5-FU modulated with leucovorin (plus bevacizumab) in patients with Metastatic Colorectal Cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 5- Fluorouracil (5-FU) | |
| DRUG | bevacizumab (Avastin) | |
| DRUG | Leucovorin | |
| DRUG | CoFactor (ANX-510) |
Timeline
- Start date
- 2006-05-01
- First posted
- 2006-06-16
- Last updated
- 2007-11-19
Locations
47 sites across 2 countries: United States, Serbia and Montenegro
Source: ClinicalTrials.gov record NCT00337389. Inclusion in this directory is not an endorsement.